Oncological safety of sentinel lymph node biopsy with single mapping tracer in cN+/ypN0 breast cancer women post-neoadjuvant chemotherapy: a real-world data study
Introduction: Sentinel lymph node biopsy (SLNB) safety after neoadjuvant therapy in initially node-positive (cN+) breast cancer remains controversial. Additionally, evidence regarding the use of a single mapping tracer in this setting is limited. Methods: Women with non-metastatic cT1–3 cN0–cN2 breast cancer who were...